Suppr超能文献

凝血因子V莱顿突变、活化蛋白C抵抗与视网膜静脉阻塞

Factor V Leiden, activated protein C resistance, and retinal vein occlusion.

作者信息

Ciardella A P, Yannuzzi L A, Freund K B, DiMichele D, Nejat M, De Rosa J T, Daly J R, Sisco L

机构信息

LuEsther T. Mertz Retinal Research Department, Manhattan Eye, Ear, and Throat Hospital, New York, New York 10021, USA.

出版信息

Retina. 1998;18(4):308-15. doi: 10.1097/00006982-199807000-00003.

Abstract

BACKGROUND

Resistance to activated protein C (APC resistance) is a thrombophilic abnormality characterized by a normal plasma level of protein C and an inherited defect in the coagulative response. This condition is believed to be caused by a point mutation in factor V, the so-called factor V Leiden, and is inherited as an autosomal dominant trait.

PURPOSE

A case-control study was carried out to evaluate the prevalence of APC resistance and factor V Leiden in patients with retinal vein occlusion (RVO) and in control subjects.

METHODS

Eighty-four consecutive RVO patients and 70 controls were tested for APC resistance with a commercial assay (Chromogenix). The first 30 patients and 47 controls were also studied for factor V Leiden. In addition, a repeat APC-resistance test was performed in 40 RVO patients and in 9 controls with a second-generation assay done to compare the reliability and reproducibility of the tests.

RESULTS

Results of testing for APC resistance with the first-generation assay revealed positive results in 38 (45%) of the study patients and 6 (9%) of the controls. The difference in frequencies of APC resistance in patients and controls was statistically significant (P < 0.0001). In the patients tested for factor V Leiden, one (3%) was a heterozygous carrier of the Arg506GIn mutation and one (2%) of the controls was a heterozygous carrier. No homozygous individuals were identified in either the study or the control groups. The difference in frequencies of factor V Leiden in study patients and controls was not statistically significant (P = 1). The repeat APC-resistance assay using factor V-deficient plasma in 40 RVO patients and 9 controls did not show any significant difference between study patients and controls or an association between APC resistance and the determination of the factor V Leiden mutant.

CONCLUSION

The first-generation commercial assay for APC resistance is not a useful screening test. The molecular test for factor V Leiden is the only definitive method. Furthermore, no significant association was found between factor V Leiden and retinal vein occlusion. Accordingly, routine testing for the presence of the factor V Leiden mutant is not advisable for patients with retinal vein occlusion.

摘要

背景

对活化蛋白C的抵抗(APC抵抗)是一种血栓形成倾向异常,其特征为血浆蛋白C水平正常且凝血反应存在遗传性缺陷。这种情况被认为是由因子V的点突变引起的,即所谓的因子V莱顿突变,并且作为常染色体显性性状遗传。

目的

进行一项病例对照研究,以评估视网膜静脉阻塞(RVO)患者和对照受试者中APC抵抗和因子V莱顿突变的患病率。

方法

使用商业检测方法(Chromogenix)对84例连续的RVO患者和70例对照进行APC抵抗检测。对前30例患者和47例对照也进行了因子V莱顿突变研究。此外,对40例RVO患者和9例对照进行了重复的APC抵抗检测,采用第二代检测方法以比较检测的可靠性和可重复性。

结果

第一代检测方法检测APC抵抗的结果显示,研究患者中有38例(45%)呈阳性,对照中有6例(9%)呈阳性。患者和对照中APC抵抗频率的差异具有统计学意义(P < 0.0001)。在检测因子V莱顿突变的患者中,1例(3%)是Arg506GIn突变的杂合携带者,对照中有1例(2%)是杂合携带者。在研究组或对照组中均未发现纯合个体。研究患者和对照中因子V莱顿突变频率的差异无统计学意义(P = 1)。在40例RVO患者和9例对照中使用缺乏因子V的血浆进行的重复APC抵抗检测未显示研究患者和对照之间有任何显著差异,也未显示APC抵抗与因子V莱顿突变体检测之间存在关联。

结论

第一代商业APC抵抗检测方法不是一种有用的筛查检测。因子V莱顿突变的分子检测是唯一的确定性方法。此外,未发现因子V莱顿突变与视网膜静脉阻塞之间存在显著关联。因此,对于视网膜静脉阻塞患者,常规检测因子V莱顿突变体的存在并不可取。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验